It was not the existence of plentiful of natural resources but the power of advanced technology of a fine chemical industry that push Germany to its present status as a wealthy, powerful nation from one of the losers devastated in World War II.
A fine chemical industry creating high added value should be arise before we cross the threshold to an advanced nation and this is also a crucial mission imposed on us looking forward to the 21st century. A report on the prospect of Korea 's industrial development listed the fine chemical industry as one of the top 10 hopeful high-tech industries for the next century.
A bulk pharmaceuticals-manufacture is a vital area of the fine chemical industry requiring endless efforts in research for sophisticated technology, a future-oriented industry of tremendous potential.
This is the very reason that Kyongbo Pharmaceutical Co., Ltd., as a specialized manufacturer of raw bulk pharmaceuticals, bears on its shoulders the burden of an enormous mission of our times.
About the time Kyongbo Pharmaceutical Co., Ltd. was founded, Korea had only a handful of raw bulk pharmaceutical manufacturers. But nowadays, there are numerous domestic manufacturers in this field, and a number of countries around the world import the raw bulk pharmaceuticals manufactured here.
Kyongbo Pharmaceutical Co., Ltd., armed with an indomitable will to become the "fastest supplier of raw bulk pharmaceuticals with the highest quality but with the lowest prices," is making all-out efforts for research and technological innovation.
Kyongbo's central R&D center was kicked off simultaneously with the foundation of the company, for the systematic introduction of advanced technology from abroad on an extensive though selective basis. At the same time, Kyongbo has made concerted efforts to recruit qualified researchers from the Korea Institute of Science and Technology and other prestigious educational and research institutions in order to develop raw materials for new drugs and new technologies and products of high economic value. Kyongbo is also committed to the development of excellent and economical raw bulk pharmaceuticals taking advantage of bioengineering, a science which will gain increasing importance as a useful tool for the fine chemical industry in the future. Firmly established as a leader in raw bulk pharmaceuticals manufacture and a pioneer in the fine chemical industry, Kyongbo will continue to grow into "an enterprise of the nation and of the world," a pro-environment company dedicated to the sacred cause of contributing to the health and welfare of the human race.
Young Eun Kim
President
|
|
